Murepavadin

N/A

Report date: 2022/04/02 11:35:17
NMEQIDP

Base Information

Drug NameMurepavadin
Drug Alias Name莫瑞伐定PEM antibiotic (POL7080) - PolyphorMurepavadinumMurepavadinaPOL-7080 +[9] 
ClassificationSmall molecules > Synthetic peptideSmall molecules > Heterocyclic drugs > Antibiotics
Mechanisms of ActionMembrane proteins inhibitors
TargetsMembrane proteins
Therapy Area/IndicationsPseudomonas aeruginosa pneumoniaRenal InsufficiencyBronchiectasis +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesThailand +[17] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPolyphor Ltd
China Registration ClassN/A

Develop Information

Active CompaniesEnBiotix IncSpexis Ltd
Inactive CompaniesF. Hoffmann-La Roche LtdPolyphor Ltd
Active IndicationsCystic FibrosisInfections
Inactive IndicationsPseudomonas aeruginosa pneumoniaRenal InsufficiencyBronchiectasis +[6] 

Other Information

ATC CodeN/A
Related LinksN/A